Cargando…
Change in Liver Fibrosis Associates with Progress of Diabetic Nephropathy in Patients with Nonalcoholic Fatty Liver Disease
Diabetic nephropathy (DN) is a major complication of diabetes. Nonalcoholic fatty liver disease (NAFLD) is common in diabetes, and liver fibrosis is a prognostic risk factor for NAFLD. The interaction between DN and liver fibrosis in NAFLD remains unclear. In 189 patients with DN and NAFLD who recei...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386534/ https://www.ncbi.nlm.nih.gov/pubmed/37513666 http://dx.doi.org/10.3390/nu15143248 |
_version_ | 1785081690315554816 |
---|---|
author | Terasaka, Yoshiko Takahashi, Hirokazu Amano, Kazushi Fujisaki, Koshiro Kita, Shotaro Kato, Kaori Nakayama, Koujin Yamashita, Yuko Nakamura, Shuji Anzai, Keizo |
author_facet | Terasaka, Yoshiko Takahashi, Hirokazu Amano, Kazushi Fujisaki, Koshiro Kita, Shotaro Kato, Kaori Nakayama, Koujin Yamashita, Yuko Nakamura, Shuji Anzai, Keizo |
author_sort | Terasaka, Yoshiko |
collection | PubMed |
description | Diabetic nephropathy (DN) is a major complication of diabetes. Nonalcoholic fatty liver disease (NAFLD) is common in diabetes, and liver fibrosis is a prognostic risk factor for NAFLD. The interaction between DN and liver fibrosis in NAFLD remains unclear. In 189 patients with DN and NAFLD who received an education course about diabetic nephropathy, liver fibrosis was evaluated using the fibrosis-4 (FIB-4) index. The association between the outcome of DN and changes in liver fibrosis was examined. The FIB-4 index was maintained at the baseline level in patients with improved DN, while it was increased in other patients. The ΔFIB-4 index was positively correlated with changes in albuminuria and proteinuria (ρ = 0.22, p = 0.004). In a multivariate analysis, changes in albuminuria and proteinuria were associated with the ΔFIB-4 index (p = 0.002). Patients with a progressive FIB-4 index category from baseline to 5 years showed a lower event-free survival rate after 5 years than patients with an improved FIB-4 index category (p = 0.037). The outcome of DN is associated with changes in liver fibrosis in patients with diabetes, NAFLD and DN. Developing a preventive and therapeutic approach for these conditions is required. |
format | Online Article Text |
id | pubmed-10386534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103865342023-07-30 Change in Liver Fibrosis Associates with Progress of Diabetic Nephropathy in Patients with Nonalcoholic Fatty Liver Disease Terasaka, Yoshiko Takahashi, Hirokazu Amano, Kazushi Fujisaki, Koshiro Kita, Shotaro Kato, Kaori Nakayama, Koujin Yamashita, Yuko Nakamura, Shuji Anzai, Keizo Nutrients Article Diabetic nephropathy (DN) is a major complication of diabetes. Nonalcoholic fatty liver disease (NAFLD) is common in diabetes, and liver fibrosis is a prognostic risk factor for NAFLD. The interaction between DN and liver fibrosis in NAFLD remains unclear. In 189 patients with DN and NAFLD who received an education course about diabetic nephropathy, liver fibrosis was evaluated using the fibrosis-4 (FIB-4) index. The association between the outcome of DN and changes in liver fibrosis was examined. The FIB-4 index was maintained at the baseline level in patients with improved DN, while it was increased in other patients. The ΔFIB-4 index was positively correlated with changes in albuminuria and proteinuria (ρ = 0.22, p = 0.004). In a multivariate analysis, changes in albuminuria and proteinuria were associated with the ΔFIB-4 index (p = 0.002). Patients with a progressive FIB-4 index category from baseline to 5 years showed a lower event-free survival rate after 5 years than patients with an improved FIB-4 index category (p = 0.037). The outcome of DN is associated with changes in liver fibrosis in patients with diabetes, NAFLD and DN. Developing a preventive and therapeutic approach for these conditions is required. MDPI 2023-07-22 /pmc/articles/PMC10386534/ /pubmed/37513666 http://dx.doi.org/10.3390/nu15143248 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Terasaka, Yoshiko Takahashi, Hirokazu Amano, Kazushi Fujisaki, Koshiro Kita, Shotaro Kato, Kaori Nakayama, Koujin Yamashita, Yuko Nakamura, Shuji Anzai, Keizo Change in Liver Fibrosis Associates with Progress of Diabetic Nephropathy in Patients with Nonalcoholic Fatty Liver Disease |
title | Change in Liver Fibrosis Associates with Progress of Diabetic Nephropathy in Patients with Nonalcoholic Fatty Liver Disease |
title_full | Change in Liver Fibrosis Associates with Progress of Diabetic Nephropathy in Patients with Nonalcoholic Fatty Liver Disease |
title_fullStr | Change in Liver Fibrosis Associates with Progress of Diabetic Nephropathy in Patients with Nonalcoholic Fatty Liver Disease |
title_full_unstemmed | Change in Liver Fibrosis Associates with Progress of Diabetic Nephropathy in Patients with Nonalcoholic Fatty Liver Disease |
title_short | Change in Liver Fibrosis Associates with Progress of Diabetic Nephropathy in Patients with Nonalcoholic Fatty Liver Disease |
title_sort | change in liver fibrosis associates with progress of diabetic nephropathy in patients with nonalcoholic fatty liver disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386534/ https://www.ncbi.nlm.nih.gov/pubmed/37513666 http://dx.doi.org/10.3390/nu15143248 |
work_keys_str_mv | AT terasakayoshiko changeinliverfibrosisassociateswithprogressofdiabeticnephropathyinpatientswithnonalcoholicfattyliverdisease AT takahashihirokazu changeinliverfibrosisassociateswithprogressofdiabeticnephropathyinpatientswithnonalcoholicfattyliverdisease AT amanokazushi changeinliverfibrosisassociateswithprogressofdiabeticnephropathyinpatientswithnonalcoholicfattyliverdisease AT fujisakikoshiro changeinliverfibrosisassociateswithprogressofdiabeticnephropathyinpatientswithnonalcoholicfattyliverdisease AT kitashotaro changeinliverfibrosisassociateswithprogressofdiabeticnephropathyinpatientswithnonalcoholicfattyliverdisease AT katokaori changeinliverfibrosisassociateswithprogressofdiabeticnephropathyinpatientswithnonalcoholicfattyliverdisease AT nakayamakoujin changeinliverfibrosisassociateswithprogressofdiabeticnephropathyinpatientswithnonalcoholicfattyliverdisease AT yamashitayuko changeinliverfibrosisassociateswithprogressofdiabeticnephropathyinpatientswithnonalcoholicfattyliverdisease AT nakamurashuji changeinliverfibrosisassociateswithprogressofdiabeticnephropathyinpatientswithnonalcoholicfattyliverdisease AT anzaikeizo changeinliverfibrosisassociateswithprogressofdiabeticnephropathyinpatientswithnonalcoholicfattyliverdisease |